Group 1 - The medical beauty sector increased by 1.0% on December 10, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3900.5, down 0.23%, while the Shenzhen Component Index closed at 13316.42, up 0.29% [1] - A table detailing the individual stock performance in the medical beauty sector is provided [1] Group 2 - In terms of capital flow, the medical beauty sector experienced a net outflow of 2.1769 million yuan from main funds, while retail funds saw a net inflow of 6.8531 million yuan [2] - Retail investors had a net outflow of 4.6763 million yuan [2] - A table showing the capital flow for individual stocks in the medical beauty sector is included [2]

Core Viewpoint - Jinbo Bio is leveraging its first-mover advantage and original innovation capabilities to establish a "license barrier" in the industry, aiming to become a world-class technology-driven bio-materials enterprise amidst increasing competition [2]. Group 1: Product Development and Innovation - Jinbo Bio has made significant breakthroughs with its core products, including the first international discovery and analysis of the atomic structure of type III collagen, which features a flexible helical structure at 164.88° [3]. - The company has developed the first original bio-material with independent intellectual property rights in China, including a broad-spectrum anti-HPV bio-protein and a multi-peptide drug for COVID-19 [3][4]. - Jinbo Bio holds three class III medical device registration certificates for recombinant human collagen, covering all dosage forms including freeze-dried fibers, solutions, and gels [3][7]. Group 2: Research and Development - The company has completed 12 projects on the atomic structure of human collagen, aiming to develop more innovative and differentiated products [4]. - Jinbo Bio has developed the "AI Collagen Brain System" to enhance research efficiency and reliability, collaborating with several universities and research institutions to establish research platforms [5]. Group 3: Industry Standards and Market Position - Jinbo Bio has participated in the formulation of multiple industry standards and is expanding into international standards, enhancing its influence in the global biopharmaceutical field [6]. - The company has maintained a leading position in the recombinant human collagen sector, despite increased competition, by leveraging its established clinical data and distribution networks [7]. Group 4: Strategic Development and Future Plans - Jinbo Bio is constructing a recombinant human collagen industrial park in collaboration with the Shanxi Comprehensive Reform Demonstration Zone to attract upstream and downstream enterprises [8]. - The company plans to enhance its product matrix and distribution channels, focusing on innovative product development and expanding market coverage through partnerships and brand promotion [8][9]. - Jinbo Bio aims to become an internationally leading bio-materials enterprise by deepening basic research and applying new technologies in the healthcare sector [9].

锦波生物（920982）12月9日大宗交易平台出现一笔成交，成交量2.50万股，成交金额750.00万元，大宗 交易成交价为300.00元，相对今日收盘价溢价28.58%。该笔交易的买方营业部为中信证券股份有限公司 大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生4笔大宗交易，合计成交金额为2124.00万元。 证券时报·数据宝统计显示，锦波生物今日收盘价为233.31元，上涨0.62%，日换手率为1.64%，成交额 为2.11亿元，近5日该股累计上涨4.42%。（数据宝） 12月9日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 2.50 | 750.00 | 300.00 | 28.58 | 中信证券股份有限公司 大连高新园区证券营业 | 华泰证券股份有限公司 南京长江路证券营业部 | | | ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） 每经讯，2025年12月9日，北交所上市公司锦波生物（920982，收盘价：233.31元）发生一笔大宗交易，成交价300元/股，成交 数量2.5万股，成交金额750万元，溢价28.58%。买入营业部是中信证券股份有限公司大连高新园区证券营业部，卖出营业部是 华泰证券股份有限公司南京长江路证券营业部。 ...

Group 1 - The core point of the article highlights a significant block trade involving Jinbo Biological, with a transaction volume of 20,000 shares and a transaction amount of 5.98 million yuan, executed at a price of 299.00 yuan, representing a premium of 32.59% over the closing price of the day [2][3] - In the past month, Jinbo Biological has recorded a total of three block trades, amounting to a cumulative transaction value of 13.74 million yuan [3] - The closing price of Jinbo Biological on the day of the block trade was 225.51 yuan, reflecting a decrease of 2.25%, with a trading volume of 2.53 billion yuan and a turnover rate of 2.00% [3] Group 2 - Jinbo Biological was established on March 28, 2008, with a registered capital of 1.1506534 billion yuan [3] - The buyer in the recent block trade was CITIC Securities Co., Ltd., Dalian High-tech Zone Securities Business Department, while the seller was Huatai Securities Co., Ltd., Nanjing Changjiang Road Securities Business Department [2][3]

Group 1 - The core point of the news is that Jinbo Biological (920982) executed a block trade on December 3, with a transaction volume of 17,000 shares and a transaction amount of 4.93 million yuan, at a price of 290.00 yuan, which represents a premium of 25.70% over the closing price of the day [2][3] - The buyer of the block trade was CITIC Securities Co., Ltd. Dalian High-tech Park Securities Business Department, while the seller was Huatai Securities Co., Ltd. Nanjing Changjiang Road Securities Business Department [2][3] - In the past month, Jinbo Biological has recorded a total of 2 block trades, with a cumulative transaction amount of 7.76 million yuan [3] Group 2 - The closing price of Jinbo Biological on the day of the block trade was 230.71 yuan, reflecting an increase of 3.26%, with a turnover rate of 2.75% and a total transaction amount of 347 million yuan [3] - Over the past five days, the stock has increased by 6.66% [3] - Jinbo Biological was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [3]

Core Viewpoint - On December 2, 2023, a block trade of 10,000 shares of Jinbo Biological (920982) was executed at a price of 283.00 CNY, representing a premium of 26.66% over the closing price of the day [2] Summary by Relevant Sections Block Trade Details - The transaction volume was 10,000 shares with a total transaction value of 2.83 million CNY [2] - The block trade price was 283.00 CNY, which is a 26.66% premium compared to the closing price of 223.43 CNY [2] - The buyer was CITIC Securities Co., Ltd. from the Dalian High-tech Zone Securities Branch, while the seller was Huatai Securities Co., Ltd. from the Nanjing Changjiang Road Securities Branch [2] Stock Performance - On the same day, Jinbo Biological's stock closed at 223.43 CNY, marking an increase of 2.42% [2] - The stock had a turnover rate of 2.05% and a total trading volume of 253 million CNY for the day [2] - Over the past five days, the stock has accumulated a rise of 3.07% [2] Company Background - Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1.1506534 billion CNY [2]

Market Overview - On December 2, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index down by 0.42%, the Shenzhen Component Index down by 0.68%, and the ChiNext Index down by 0.69% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 1,593.43 billion yuan, a decrease of about 280.51 billion yuan compared to the previous trading day [1] - Out of the total stocks, 1,544 rose while 3,740 fell, with 54 hitting the daily limit up and 7 hitting the daily limit down [1] Sector Performance - The sectors that performed well included Fujian state-owned assets, forestry, prepared dishes, coal mining, airports, and light manufacturing [1] - Conversely, sectors that saw declines included non-ferrous metals, antimony, MLCC, lithium mining, energy metals, precious metals, and bioproducts [1] Commodity Futures - In the domestic commodity futures market, there were mixed results, with BR rubber rising by approximately 4%, and silver and pulp increasing by over 2% [1] - Other commodities such as coking coal and soda ash saw increases of over 1%, while asphalt and platinum fell by more than 2% [1] Shanxi Sector Analysis - In the Shanxi sector on December 2, there were 41 stocks, with 12 rising and 27 falling, indicating a significant number of declines [2] - Among the rising stocks, Antai Group led with a peak increase of 9.96%, while Taiyuan Iron & Steel rose by 7.06% [2] - Other notable gainers included Huayang Co. with a 3.57% increase, Jinbo Biological with a 2.42% increase, and Yongtai Energy with a 1.23% increase [2] - The leading decliner was Dongjie Intelligent, which fell by 3.62%, followed by Beifang Copper, Pailin Biological, Keda Automation, and Kuaijingtong with respective declines of 2.69%, 2.32%, 2.01%, and 1.72% [2]

北京商报讯（记者王寅浩宋雨盈）11月24日，锦波生物发布公告称，公司重组Ⅲ型人源化胶原蛋白冻干 纤维获得菲律宾主管当局颁发的D类医疗器械注册证，根据公告，该产品适用于面部真皮组织填充以纠 正额部动力性皱纹（包括眉间纹、额头纹和鱼尾纹）。 （文章来源：北京商报） ...

从资金流向上来看，当日医疗美容板块主力资金净流出5875.57万元，游资资金净流入1690.61万元，散户 资金净流入4184.96万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月24日医疗美容板块较上一交易日上涨0.27%，*ST美谷领涨。当日上证指数报收于 3836.77，上涨0.05%。深证成指报收于12585.08，上涨0.37%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.07 | 4.63% | 28.52万 | | 1.15亿 | | 688363 | 华熙生物 | 49.78 | 1.86% | 1.87万 | | 9268.75万 | | 300896 | 爱美客 | 66'56 | -1.36% | 2.41万 | | 3.52亿 | | 920982 | 锦波生物 | 216.59 | -1.55% | 7336.92 | | 1.60亿 | | 代码 | 名称 | 主力净流 ...